Engineered immune cells take aim at tough T-Cell cancers

NCT ID NCT07070323

First seen Nov 19, 2025 · Last updated Jun 14, 2026 · Updated 24 times

Summary

This study tests a new treatment called CD5-CAR T cells for people with T-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own or a donor's immune cells, which are modified in a lab to better attack the cancer. The goal is to find the safest dose and see if it can shrink tumors. About 54 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102206, China

  • Shanghai Liquan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201418, China

  • The General Hospital of Western Theater Command PLA

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610083, China

  • Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

    RECRUITING

    Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.